Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above 200-Day Moving Average – Here’s What Happened

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.59. Xtant Medical shares last traded at $0.56, with a volume of 37,022 shares traded.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum set a $1.50 price target on shares of Xtant Medical and gave the stock a “buy” rating in a report on Friday, October 18th.

Xtant Medical Price Performance

The firm has a market capitalization of $77.85 million, a PE ratio of -4.31 and a beta of 0.35. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings results on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The firm had revenue of $27.94 million during the quarter. Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%.

Institutional Investors Weigh In On Xtant Medical

A hedge fund recently raised its stake in Xtant Medical stock. Geode Capital Management LLC grew its stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 515,006 shares of the medical device company’s stock after purchasing an additional 212,394 shares during the period. Geode Capital Management LLC owned approximately 0.37% of Xtant Medical worth $348,000 as of its most recent SEC filing. 69.33% of the stock is currently owned by institutional investors.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.